Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer
-
- Aoshima Hiroyuki
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Tawarahara Kei
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Kato Haruta
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Ishibashi Fumimaro
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Tokonami Yuki
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Nakamura Naoki
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Matsukura Gaku
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Kanda Takahiro
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Ozeki Mariko
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Ukigai Hiroshi
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
-
- Takeuchi Ryosuke
- Department of Cardiology, Hamamatsu Red Cross Hospital, Japan
Abstract
<p>Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, may be associated with arterial embolisms. We herein report a case of acute myocardial infarction caused by coronary embolism during combination chemotherapy with mFOLFOX-6 and bevacizumab in a patient with metastatic colon cancer. Thromboembolism occurred only in the distal right posterolateral branch without stenotic lesions or plaque rupture in the proximal branch of the right coronary artery. Sole thromboaspiration was successfully performed; the final angiogram demonstrated no stenosis in the right coronary artery. Bevacizumab may be associated with acute coronary syndrome in patients with coronary risk factors, despite no significant coronary narrowing. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 62 (16), 2361-2364, 2023-08-15
The Japanese Society of Internal Medicine